Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes

Studied

Researchers used physician-checked automated extraction of US clinical notes from 2020–2026 to describe BPC-157 use and reported outcomes.

Who / model

There were 1,039 documented users. Responses were recorded for 354; use averaged 2.2 months among the 130 with documented duration.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Among users with recorded responses, 79% reported improvement and 5% worsening. Neuropsychiatric, injection-site and digestive adverse events were also recorded.

Limits

Response direction was missing for 65.9%. Co-treatments, reporting biases and imperfect extraction prevent conclusions about effectiveness. Adverse events were probably under-reported.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary